tradingkey.logo

HUTCHMED (China) Ltd

HCM
View Detailed Chart

17.040USD

-0.410-2.35%
Close 09/19, 16:00ETQuotes delayed by 15 min
14.86BMarket Cap
--P/E TTM

HUTCHMED (China) Ltd

17.040

-0.410-2.35%
Intraday
1m
30m
1h
D
W
M
D

Today

-2.35%

5 Days

-4.96%

1 Month

+5.12%

6 Months

+5.32%

Year to Date

+18.25%

1 Year

+1.37%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
115 / 175
Overall Ranking
411 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 12 analysts
Buy
Current Rating
21.569
Target Price
+23.61%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 47.79% year-on-year.
Undervalued
The company’s latest PE is 31.51, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.97M shares, decreasing 47.54% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 129.00K shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Ticker SymbolHCM
CompanyHUTCHMED (China) Ltd
CEODr. Weiguo Su, Ph.D.
Websitehttps://www.hutch-med.com/
KeyAI